BioLineRx (NASDAQ:BLRX) is about to face one of its defining moments in 1Q 2013, when results of an interim analysis from the phase 2/3 CLARITY study of BL-1020 are expected to be released. BL-1020, BioLine's leading drug candidate, is an orally available GABA-enhanced antipsychotic for the treatment of both the positive and cognitive effects of schizophrenia. The cognitive impairment associated with schizophrenia (OTC:CIAS), which is less recognized than the positive effects of the condition (reasonably treated by current antipsychotics), is exhibited as deterioration of long-term memory, concentration and ability to perform executive functions. CIAS affects the vast majority of schizophrenia patients and severely damages their overall functional and quality of life outcomes.
We think that the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|